Hemab Therapeutics Holdings, Inc. Common Stock

NASDAQ: COAG · Healthcare · Biotechnology

PublicHQ Cambridge, MA · MiddlesexCIK 0002114044Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 38

v0.1 · 5/100 weight · pillars only

↑ market scale, workforce scale · ↓ listing tenure, filing timeliness

Methodology →

Revenue TTM

—

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

—

Employees

Market cap

$62.3M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

No filed financials — private or non-XBRL filer.

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Hemab Therapeutics Holdings, Inc. Common Stock has no structured financials on file — private or non-XBRL filer.

Peers · Healthcare

OnKure Therapeutics, Inc.44D Clene Inc.27D Elicio Therapeutics, Inc.26D Cibus, Inc.43D

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Alnylam Pharmaceuticals, Inc.$3.7B79B+

Key facts

CEOBenny Sorensen

SectorHealthcare

IndustryBiotechnology

HeadquartersCambridge, MA

ExchangeNASDAQ: COAG

Employees59

IPO date2026-05-01

Latest filings

10-Q2026-05-21 8-K2026-05-21 8-K2026-05-11 8-K2026-05-04

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.